{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:24:32Z","timestamp":1783088672441,"version":"3.54.6"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nonalcoholic fatty liver disease (NAFLD), which includes simple steatosis, steatohepatitis, fibrosis, and cirrhosis, is characterised by abnormal fat accumulation in the liver in the absence of excessive alcohol intake. In patients with type 2 diabetes (T2D), concurrent NAFLD might increase the risk of chronic kidney disease and the mortality rate. Although several studies have examined the effectiveness of pentoxifylline (PTX) in NAFLD treatment, no results are available to verify the effectiveness of PTX in treating T2D associated with NAFLD. In this study, we developed a combined high-fat diet-induced obesity and low-dose streptozocin-induced hyperglycaemia mouse model to mimic the concurrent NAFLD and T2D pathological condition. By combining physiological assessments, pathological examinations, metabolomics studies on blood, urine, and liver, and measurements of gene and protein expression, we elucidated the effectiveness and the underlying mechanism of action of PTX in the hyperglycaemic and dyslipidaemic mice. Our results revealed that PTX ameliorated NAFLD in the hyperglycaemic and dyslipidaemic mice by upregulating fatty acid \u03b2-oxidation. Furthermore, the glycolysis pathway and branched-chain amino acid-related pathways in these mice were restored by PTX.<\/jats:p>","DOI":"10.1038\/srep33102","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T12:51:00Z","timestamp":1473425460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid \u03b2-oxidation"],"prefix":"10.1038","volume":"6","author":[{"given":"Jia-Hung","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Ling","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Huang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiunn-Wang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Heng","family":"Pao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"key":"BFsrep33102_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221\u20131231 (2002).","journal-title":"N Engl J Med"},{"key":"BFsrep33102_CR2","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.2174\/13816128113199990336","volume":"19","author":"N Bhala","year":"2013","unstructured":"Bhala, N., Jouness, R. I. & Bugianesi, E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 19, 5169\u20135176 (2013).","journal-title":"Curr Pharm Des"},{"key":"BFsrep33102_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2005.02.042","volume":"43","author":"JG Fan","year":"2005","unstructured":"Fan, J. G. et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43, 508\u2013514 (2005).","journal-title":"J Hepatol"},{"key":"BFsrep33102_CR4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","volume":"22","author":"S Jimba","year":"2005","unstructured":"Jimba, S. et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 22, 1141\u20131145 (2005).","journal-title":"Diabet Med"},{"key":"BFsrep33102_CR5","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/ajg.2012.314","volume":"107","author":"YM Kwon","year":"2012","unstructured":"Kwon, Y. M. et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 107, 1852\u20131858 (2012).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep33102_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000282080","volume":"28","author":"S Bellentani","year":"2010","unstructured":"Bellentani, S., Scaglioni, F., Marino, M. & Bedogni, G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28, 155\u2013161 (2010).","journal-title":"Dig Dis"},{"key":"BFsrep33102_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mnfr.201300522","volume":"58","author":"MH Pan","year":"2014","unstructured":"Pan, M. H., Lai, C. S., Tsai, M. L. & Ho, C. T. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res 58, 147\u2013171 (2014).","journal-title":"Mol Nutr Food Res"},{"key":"BFsrep33102_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/hep.23784","volume":"52","author":"BA Neuschwander-Tetri","year":"2010","unstructured":"Neuschwander-Tetri, B. A. et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 52, 913\u2013924 (2010).","journal-title":"Hepatology"},{"key":"BFsrep33102_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1478-3231.2008.01718.x","volume":"29","author":"NC Leite","year":"2009","unstructured":"Leite, N. C., Salles, G. F., Araujo, A. L., Villela-Nogueira, C. A. & Cardoso, C. R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 29, 113\u2013119 (2009).","journal-title":"Liver Int"},{"key":"BFsrep33102_CR10","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413\u20131419 (1999).","journal-title":"Gastroenterology"},{"key":"BFsrep33102_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","volume":"51","author":"G Targher","year":"2008","unstructured":"Targher, G. et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51, 444\u2013450 (2008).","journal-title":"Diabetologia"},{"key":"BFsrep33102_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ajg.2010.18","volume":"105","author":"LA Adams","year":"2010","unstructured":"Adams, L. A. et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105, 1567\u20131573 (2010).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep33102_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M., Targher, G. & Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature reviews. Gastroenterology & hepatology 10, 330\u2013344 (2013).","journal-title":"Nature reviews. Gastroenterology & hepatology"},{"key":"BFsrep33102_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1177\/1756283X16638830","volume":"9","author":"S Zelber-Sagi","year":"2016","unstructured":"Zelber-Sagi, S., Godos, J. & Salomone, F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol 9, 392\u2013407 (2016).","journal-title":"Therap Adv Gastroenterol"},{"key":"BFsrep33102_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3109\/08941939.2013.835454","volume":"27","author":"P Genoves","year":"2014","unstructured":"Genoves, P. et al. Pentoxifylline in liver ischemia and reperfusion. J. Invest. Surg. 27, 114\u2013124 (2014).","journal-title":"J. Invest. Surg."},{"key":"BFsrep33102_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11901-012-0158-y","volume":"12","author":"L Smart","year":"2013","unstructured":"Smart, L., Gobejishvili, L., Crittenden, N., Barve, S. & McClain, C. J. Alcoholic Hepatitis: Steroids vs. Pentoxifylline. Current hepatitis reports 12, 59\u201365 (2013).","journal-title":"Current hepatitis reports"},{"key":"BFsrep33102_CR17","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/hep.25778","volume":"56","author":"CO Zein","year":"2012","unstructured":"Zein, C. O. et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 56, 1291\u20131299 (2012).","journal-title":"Hepatology"},{"key":"BFsrep33102_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0306-3623(96)00314-X","volume":"29","author":"C Windmeier","year":"1997","unstructured":"Windmeier, C. & Gressner, A. M. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 29, 181\u2013196 (1997).","journal-title":"Gen Pharmacol"},{"key":"BFsrep33102_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/01.mog.0000182863.96421.47","volume":"21","author":"S Choi","year":"2005","unstructured":"Choi, S. & Diehl, A. M. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 21, 702\u2013707 (2005).","journal-title":"Curr Opin Gastroenterol"},{"key":"BFsrep33102_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1476-511X-10-49","volume":"10","author":"W Li","year":"2011","unstructured":"Li, W. et al. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 10, 49 (2011).","journal-title":"Lipids Health Dis"},{"key":"BFsrep33102_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","volume":"67","author":"B Fromenty","year":"1995","unstructured":"Fromenty, B. & Pessayre, D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67, 101\u2013154 (1995).","journal-title":"Pharmacol Ther"},{"key":"BFsrep33102_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3748\/wjg.14.193","volume":"14","author":"Y Wei","year":"2008","unstructured":"Wei, Y., Rector, R. S., Thyfault, J. P. & Ibdah, J. A. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 14, 193\u2013199 (2008).","journal-title":"World J Gastroenterol"},{"key":"BFsrep33102_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/2231-4040.90879","volume":"2","author":"S Tyagi","year":"2011","unstructured":"Tyagi, S., Gupta, P., Saini, A. S., Kaushal, C. & Sharma, S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res 2, 236\u2013240 (2011).","journal-title":"J Adv Pharm Technol Res"},{"key":"BFsrep33102_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.mito.2008.02.001","volume":"8","author":"WA Alaynick","year":"2008","unstructured":"Alaynick, W. A. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 8, 329\u2013337 (2008).","journal-title":"Mitochondrion"},{"key":"BFsrep33102_CR25","doi-asserted-by":"publisher","first-page":"27950","DOI":"10.1074\/jbc.M100258200","volume":"276","author":"MH Hsu","year":"2001","unstructured":"Hsu, M. H., Savas, U., Griffin, K. J. & Johnson, E. F. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem 276, 27950\u201327958 (2001).","journal-title":"J Biol Chem"},{"key":"BFsrep33102_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0005-2760(96)00066-5","volume":"1302","author":"K Schoonjans","year":"1996","unstructured":"Schoonjans, K., Staels, B. & Auwerx, J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302, 93\u2013109 (1996).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep33102_CR27","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","volume":"1821","author":"A Tailleux","year":"2012","unstructured":"Tailleux, A., Wouters, K. & Staels, B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821, 809\u2013818 (2012).","journal-title":"Biochim Biophys Acta"},{"key":"BFsrep33102_CR28","doi-asserted-by":"publisher","first-page":"e96969","DOI":"10.1371\/journal.pone.0096969","volume":"9","author":"J Chao","year":"2014","unstructured":"Chao, J. et al. Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. PLoS One 9, e96969 (2014).","journal-title":"PLoS One"},{"key":"BFsrep33102_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/jdi.12235","volume":"5","author":"S Skovso","year":"2014","unstructured":"Skovso, S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. Journal of diabetes investigation 5, 349\u2013358 (2014).","journal-title":"Journal of diabetes investigation"},{"key":"BFsrep33102_CR30","doi-asserted-by":"publisher","first-page":"416254","DOI":"10.1155\/2011\/416254","volume":"2011","author":"ER Gilbert","year":"2011","unstructured":"Gilbert, E. R., Fu, Z. & Liu, D. Development of a nongenetic mouse model of type 2 diabetes. Exp Diabetes Res 2011, 416254 (2011).","journal-title":"Exp Diabetes Res"},{"key":"BFsrep33102_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nm.4057","volume":"22","author":"C Jang","year":"2016","unstructured":"Jang, C. et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med 22, 421\u2013426 (2016).","journal-title":"Nat Med"},{"key":"BFsrep33102_CR32","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1016\/S0021-9258(20)81813-4","volume":"247","author":"MG Buse","year":"1972","unstructured":"Buse, M. G., Biggers, J. F., Friderici, K. H. & Buse, J. F. Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat. The effect of fatty acids, glucose, and pyruvate respiration. J Biol Chem 247, 8085\u20138096 (1972).","journal-title":"J Biol Chem"},{"key":"BFsrep33102_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2009.02.002","volume":"9","author":"CB Newgard","year":"2009","unstructured":"Newgard, C. B. et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9, 311\u2013326 (2009).","journal-title":"Cell Metab"},{"key":"BFsrep33102_CR34","doi-asserted-by":"publisher","first-page":"e1004559","DOI":"10.1371\/journal.ppat.1004559","volume":"11","author":"J Boursier","year":"2015","unstructured":"Boursier, J. & Diehl, A. M. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog 11, e1004559 (2015).","journal-title":"PLoS Pathog"},{"key":"BFsrep33102_CR35","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/pr300900b","volume":"12","author":"HJ Lees","year":"2013","unstructured":"Lees, H. J., Swann, J. R., Wilson, I. D., Nicholson, J. K. & Holmes, E. Hippurate: the natural history of a mammalian-microbial cometabolite. J Proteome Res 12, 1527\u20131546 (2013).","journal-title":"J Proteome Res"},{"key":"BFsrep33102_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.2047-6310.2012.00087.x","volume":"8","author":"SE McCormack","year":"2013","unstructured":"McCormack, S. E. et al. Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents. Pediatr Obes 8, 52\u201361 (2013).","journal-title":"Pediatr Obes"},{"key":"BFsrep33102_CR37","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1139\/H07-083","volume":"32","author":"DM Muoio","year":"2007","unstructured":"Muoio, D. M. & Koves, T. R. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. Appl Physiol Nutr Metab 32, 874\u2013883 (2007).","journal-title":"Appl Physiol Nutr Metab"},{"key":"BFsrep33102_CR38","doi-asserted-by":"publisher","first-page":"4963","DOI":"10.1242\/jcs.113662","volume":"125","author":"S Austin","year":"2012","unstructured":"Austin, S. & St-Pierre, J. PGC1alpha and mitochondrial metabolism\u2013emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci 125, 4963\u20134971 (2012).","journal-title":"J Cell Sci"},{"key":"BFsrep33102_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature08821","volume":"464","author":"J Qin","year":"2010","unstructured":"Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59\u201365 (2010).","journal-title":"Nature"},{"key":"BFsrep33102_CR40","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/sj.embor.7400731","volume":"7","author":"AM O\u2019Hara","year":"2006","unstructured":"O\u2019Hara, A. M. & Shanahan, F. The gut flora as a forgotten organ. EMBO Rep 7, 688\u2013693 (2006).","journal-title":"EMBO Rep"},{"key":"BFsrep33102_CR41","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","volume":"373","author":"AG Tabak","year":"2009","unstructured":"Tabak, A. G. et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373, 2215\u20132221 (2009).","journal-title":"Lancet"},{"key":"BFsrep33102_CR42","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/hep.27999","volume":"62","author":"S Singh","year":"2015","unstructured":"Singh, S., Khera, R., Allen, A. M., Murad, M. H. & Loomba, R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 62, 1417\u20131432 (2015).","journal-title":"Hepatology"},{"key":"BFsrep33102_CR43","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1476-5381.2011.01580.x","volume":"165","author":"J Massart","year":"2012","unstructured":"Massart, J. et al. Pentoxifylline aggravates fatty liver in obese and diabetic ob\/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. Br J Pharmacol 165, 1361\u20131374 (2012).","journal-title":"Br J Pharmacol"},{"key":"BFsrep33102_CR44","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.4254\/wjh.v7.i24.2551","volume":"7","author":"SC Acedo","year":"2015","unstructured":"Acedo, S. C. et al. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World J Hepatol 7, 2551\u20132558 (2015).","journal-title":"World J Hepatol"},{"key":"BFsrep33102_CR45","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/aps.2010.110","volume":"31","author":"J Wu","year":"2010","unstructured":"Wu, J., Zhao, M. Y., Zheng, H., Zhang, H. & Jiang, Y. Pentoxifylline alleviates high-fat diet-induced non-alcoholic steatohepatitis and early atherosclerosis in rats by inhibiting AGE and RAGE expression. Acta Pharmacol Sin 31, 1367\u20131375 (2010).","journal-title":"Acta Pharmacol Sin"},{"key":"BFsrep33102_CR46","doi-asserted-by":"crossref","unstructured":"Marventano, S. et al. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies. Clin Nutr (2016).","DOI":"10.1016\/j.clnu.2016.03.012"},{"key":"BFsrep33102_CR47","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt, S. Y. & Vander Heiden, M. G. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27, 441\u2013464 (2011).","journal-title":"Annu Rev Cell Dev Biol"},{"key":"BFsrep33102_CR48","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1126\/science.1058079","volume":"292","author":"T Pfeiffer","year":"2001","unstructured":"Pfeiffer, T., Schuster, S. & Bonhoeffer, S. Cooperation and competition in the evolution of ATP-producing pathways. Science 292, 504\u2013507 (2001).","journal-title":"Science"},{"key":"BFsrep33102_CR49","doi-asserted-by":"publisher","first-page":"14007","DOI":"10.1074\/jbc.M110.183517","volume":"286","author":"ES Di Cairano","year":"2011","unstructured":"Di Cairano, E. S. et al. The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. J Biol Chem 286, 14007\u201314018 (2011).","journal-title":"J Biol Chem"},{"key":"BFsrep33102_CR50","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/oby.2008.32","volume":"16","author":"MY Chan","year":"2008","unstructured":"Chan, M. Y., Zhao, Y. & Heng, C. K. Sequential responses to high-fat and high-calorie feeding in an obese mouse model. Obesity (Silver Spring) 16, 972\u2013978 (2008).","journal-title":"Obesity (Silver Spring)"},{"key":"BFsrep33102_CR51","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola, C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64, 800\u2013812 (2015).","journal-title":"Gut"},{"key":"BFsrep33102_CR52","doi-asserted-by":"publisher","first-page":"613","DOI":"10.4254\/wjh.v6.i8.613","volume":"6","author":"M Celikbilek","year":"2014","unstructured":"Celikbilek, M. et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 6, 613\u2013620 (2014).","journal-title":"World J Hepatol"},{"key":"BFsrep33102_CR53","doi-asserted-by":"publisher","first-page":"741465","DOI":"10.1155\/2014\/741465","volume":"2014","author":"M Gori","year":"2014","unstructured":"Gori, M., Arciello, M. & Balsano, C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. BioMed research international 2014, 741465 (2014).","journal-title":"BioMed research international"},{"key":"BFsrep33102_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412\u2013419 (1985).","journal-title":"Diabetologia"},{"key":"BFsrep33102_CR55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/01926230252824761","volume":"30","author":"C Shackelford","year":"2002","unstructured":"Shackelford, C., Long, G., Wolf, J., Okerberg, C. & Herbert, R. Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 30, 93\u201396 (2002).","journal-title":"Toxicol Pathol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep33102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33102","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:48:21Z","timestamp":1672879701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep33102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep33102"],"URL":"https:\/\/doi.org\/10.1038\/srep33102","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,9]]},"assertion":[{"value":"25 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33102"}}